N/A N=310 Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers
Veteran · Smoking Cessation
Primary: Number of Participants With Abstinence or Non-Abstinence at 6-month Follow-up — 38; 40; 77; 83 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Non-arteritic Ischemic Optic Neuropathy · Optic Nerve Injuries
Primary: Mean Increase From Baseline in ETDRS Letters Read at 26 Weeks and Off-drug Follow-up Visit — 15; 7; 9; 6 EDTRS Letters
Phase 2 N=3 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants
Phase 4 N=447 PRET: Patients Prone to Recurrence After Endovascular Treatment
Intracranial Aneurysm · Subarachnoid Hemorrhage
Primary: Recurrence Rate of Target Aneurysm. — 102; 103 Participants
Phase 4 N=380 Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
Essential Hypertension · Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12 — 59.8; 65.9…
Early Phase 1 N=19 Intensity Modulated Radiation Therapy for Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…
N/A N=16 Metabolic Costs of Walking Post Stroke
Acute Stroke
Primary: Maximum Exercise Tolerance Testing
Phase 1 N=48 Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) Over One Dosing Interval for Diclofenac at Steady State (AUC0-τ,ss) (τ = 12 Hours) (Day 7) — 46.855; 40.175; 83.644…
Phase 2 N=164 Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Colorectal Carcinoma
Primary: Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization — 46.4; 47.4 percentage of participants
Phase 1 N=32 A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis
Healthy · Atopic Dermatitis
Primary: Cohort 1: Skin Irritation Index — 40.0; 5.0 scores on a scale
Phase 1 N=26 A Study of Japanese Rheumatoid Arthritis Participants
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 0; 0; 0; 0 Participants
Phase 1 N=28 A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
Diabetes Mellitus, Type 1
Primary: Pharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro — 677.84; 716.52…
Phase 4 N=20 Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
Acne
Primary: Percent of Subjects Who Achieve at Least a Two Grade Improvement and a Rating of Clear or Almost Clear on the Investigator Global Assessment (IGA) Scale — 0; 3; 7…
Phase 3 N=707 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 10.2; 8.0 months — p=0.0049
Phase 1 N=9 Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
Malignant Solid Tumor · Metastatic EphA2 Positive Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 4; 3; 0; 1 Participants